Biogen Doubles Down On Alzheimer’s and Neuroscience With Sangamo Gene Regulation Deal

Deal Worth Up To $2.37bn

 
• By Andrew McConaghie
  
Biogen_Switzerland
Biogen's filing of aducanumab is the most anticipated biopharma sector event in 2020
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip